Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL): Sees good news on its rheumatoid arthritis drug. Jumps to $26.45 up from 52-week low of $6.64.

Savient Pharmaceuticals, Inc. (NASDAQ: SVNT): Gets strong results from late stage trials for drug which effectively treated patients with gout. Shares move up to $18.58 from 52-week low of $10.58.

BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN): FDA approves company's new drug. Stock up to $30.49 and more after hours from 52-week low of $15.53.

Coca-Cola Enterprises Inc. (NYSE: CCE): Has a strong earnings outlook for next year. Moves up to $26.83 from 52-week low of $19.78.

PepsiCo, Inc. (NYSE: PEP): No news. Just a safe, successful place to put money. Up to $78.78 from 52-week low of $61.89.

Douglas A. McIntyre is an editor at 247wallst.com.

MOST NOTEWORTHY: Global pharmaceutical stocks, Rigel Pharmaceuticals and Brightpoint were today's noteworthy initiations:

• Bernstein initiated global pharmaceutical stocks with a Cautious view. The firm initiated Merck & Co Inc (NYSE: MRK), Schering Plough Corporation (NYSE: SGP) and Wyeth (NYSE: WYE) with Outperform ratings, as well as Bristol-Myers Squibb Company (NYSE: BMY) and Eli Lilly & Company (NYSE: LLY) with Market Perform ratings.
  
• CIBC resumed coverage of Rigel Pharmaceuticals Inc (NASDAQ: RIGL) with a Sector Outperformer rating and $16 target. The firm expects near-term upside to be driven by positive phase 2 results of R788 in rheumatoid arthritis, expected in December, and thinks the company's strong scientific platform will support long-term appreciation.
  
• Bear Stearns started Brightpoint Incorporated (NASDAQ: CELL) with an Outperform rating and $20 target, as they are positive on Brightpoint's merger with Dangaard given the significant synergies and diversification it provides.

OTHER INITIATIONS:

• Genitope Corporation (NASDAQ: GTOP) was initiated with a Neutral rating at Merriman.
  
• Grubb & Ellis Company (NYSE: GBE) was reinstated with an Outperform rating at William Blair.
  
• Roth Capital started Emcore Corporation (NASDAQ: EMKR) with a Buy rating and $13.80 target.
  
• Morgan Stanley started ING Groep NV (NYSE: ING) with an Equal Weight rating.